Workflow
直流压缩雾化器
icon
Search documents
可孚医疗:康复辅具类产品表现亮眼,健耳业务有望实现扭亏转盈-20250521
China Post Securities· 2025-05-21 03:23
Investment Rating - The investment rating for the company is "Buy" [17] Core Views - The company has shown a strong performance in its rehabilitation aids segment, with a significant revenue increase of 42.77% year-on-year [6] - The company is focusing on core product categories and enhancing R&D efficiency, leading to rapid innovation and product launches [7] - The hearing aid business is developing steadily, with a revenue growth of 37.86% year-on-year, indicating potential for becoming a second growth curve for the company [10] Company Overview - The latest closing price is 32.97 yuan, with a total market capitalization of 6.9 billion yuan [4] - The company reported a revenue of 2.983 billion yuan in 2024, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.60% [5] - The company has a debt-to-asset ratio of 25.2% and a price-to-earnings ratio of 21.55 [4] Financial Performance - The company expects revenues of 3.449 billion yuan, 4.032 billion yuan, and 4.747 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 15.6%, 16.9%, and 17.7% [11] - The projected net profit for 2025, 2026, and 2027 is 389 million yuan, 454 million yuan, and 564 million yuan, with growth rates of 24.9%, 16.7%, and 24.0% respectively [11] - The company has launched over a hundred new products in 2024, enhancing its product portfolio significantly [7]
可孚医疗(301087):康复辅具类产品表现亮眼,健耳业务有望实现扭亏转盈
China Post Securities· 2025-05-21 03:09
Investment Rating - The report assigns a "Buy" rating for the stock, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [17]. Core Insights - The company, Kefu Medical, reported a revenue of 2.983 billion yuan for 2024, a year-on-year increase of 4.53%, and a net profit attributable to shareholders of 312 million yuan, up 22.60% year-on-year [5]. - The company is focusing on home medical care, with significant growth in rehabilitation aids, which generated 1.104 billion yuan in revenue, a 42.77% increase [6]. - Kefu Medical launched over a hundred new products in 2024, enhancing its product portfolio in the high-end respiratory support field and other medical devices [7]. - The company has established a multi-channel marketing strategy, achieving 1.990 billion yuan in online sales, a growth of 8.94% [8]. - The hearing aid business is developing steadily, with a revenue of 273 million yuan in 2024, reflecting a growth of 37.86% [10]. - Revenue projections for 2025-2027 are 3.449 billion yuan, 4.032 billion yuan, and 4.747 billion yuan, with corresponding net profits of 389 million yuan, 454 million yuan, and 564 million yuan [11]. Financial Summary - As of the latest report, the company's total market capitalization is 6.9 billion yuan, with a price-to-earnings ratio of 21.55 [4]. - The company’s asset-liability ratio stands at 25.2%, indicating a solid financial position [4]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.86 yuan, 2.17 yuan, and 2.70 yuan respectively [11].
可孚医疗(301087):产品丰富+渠道多元,收入增长持续稳健
Huaan Securities· 2025-05-04 13:11
| [Table_BaseData] 收盘价(元) | 33.50 | | --- | --- | | 近 12 个月最高/最低(元) | 47.50/28.10 | | 总股本(百万股) | 209 | | 流通股本(百万股) | 194 | | 流通股比例(%) | 92.90 | | 总市值(亿元) | 70 | | 流通市值(亿元) | 65 | [公司价格与沪深 Table_Chart] 300 走势比较 可孚医疗( [Table_StockNameRptType] 301087) 公司点评 产品丰富+渠道多元,收入增长持续稳健 | 投资评级:买入(维持) [Table_Rank] | | --- | | 报告日期: 2025-05-04 | -31% -16% -2% 13% 28% 5/24 8/24 11/24 2/25 可孚医疗 沪深300 [Table_Author] 分析师:谭国超 执业证书号:S0010521120002 邮箱:tangc@hazq.com 分析师:李婵 执业证书号:S0010523120002 邮箱:lichan@hazq.com [Table_CompanyRepo ...
可孚医疗:产品丰富+渠道多元,收入增长持续稳健-20250504
Huaan Securities· 2025-05-04 12:23
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady revenue growth with a diverse product range and multiple sales channels, achieving a revenue of 2.983 billion yuan in 2024, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.60% year-on-year [5][9] - The company focuses on core product categories and enhances R&D efficiency, launching over a hundred new products, including innovative solutions for chronic disease management [6] - The online sales channel generated 1.990 billion yuan in revenue, a growth of 8.94% year-on-year, while the offline channel saw a decline of 3.12% [7][8] Financial Performance Summary - In 2024, the company achieved a revenue of 2.983 billion yuan, with a net profit of 312 million yuan and a gross margin of 51.9% [11] - Revenue projections for 2025-2027 are 3.580 billion yuan, 4.333 billion yuan, and 5.236 billion yuan, with corresponding net profits of 414 million yuan, 504 million yuan, and 613 million yuan [9][11] - The expected EPS for 2025-2027 is 1.98 yuan, 2.41 yuan, and 2.93 yuan, with P/E ratios of 17x, 14x, and 11x respectively [9][11]
可孚医疗年赚3.12亿分红3.66亿 经营现金流强劲货币资金近13亿
Chang Jiang Shang Bao· 2025-04-30 17:21
长江商报消息知名产品"背背佳"生产商可孚医疗(301087)(301087.SZ)交出了一份亮眼的成绩单。 4月28日晚间,可孚医疗披露2024年年报,公司全年实现营业收入29.83亿元,同比增长4.53%;实现归 属于母公司的净利润(以下简称"净利润")3.12亿元,同比增长22.6%。 对于业绩增长,可孚医疗表示,主要得益于核心产品线的持续放量及产品结构优化。公司不断强化核心 产品的技术攻关与市场拓展力度,推动相关业务实现快速增长。 长江商报记者注意到,可孚医疗在行业内率先布局线上业务,形成国内主要第三方电商平台全面布局。 2024年公司线上渠道收入19.9亿元,同比增长8.94%,其中抖音、快手等兴趣电商渠道表现尤为突出。 可孚医疗延续高额分红传统,拟全体股东每10股派发现金红利12元,合计派发现金红利约2.44亿元。加 上2024年中期分红,公司全年累计分红将达3.66亿元,占净利润的117.31%。 全年营收净利双增 作为一家医疗器械行业公司,在前几年,可孚医疗可以说赚得盆满钵满。 回顾历史数据,2020年可孚医疗实现营业收入23.75亿元,同比增长62.45%;净利润4.25亿元,同比增 长242 ...